Mark A. Goldsmith - Jun 16, 2025 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Stock symbol
RVMD
Transactions as of
Jun 16, 2025
Transactions value $
-$537,546
Form type
4
Date filed
6/18/2025, 04:06 PM
Previous filing
Mar 19, 2025
Next filing
Jul 2, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GOLDSMITH MARK A President and Chief Executive Officer, Director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY /s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith 2025-06-18 0001246842

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Sale -$538K -13.5K -3.05% $39.83 429K Jun 16, 2025 Direct F1, F2, F3, F4
holding RVMD Common Stock 20.4K Jun 16, 2025 Trust F5
holding RVMD Common Stock 20.4K Jun 16, 2025 Trust F6
holding RVMD Common Stock 466K Jun 16, 2025 Trust F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
F2 This transaction was executed in multiple trades in prices ranging from $39.6016 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
F4 Includes 218,188 RSUs.
F5 Held by Jonathan Goldsmith Revocable Trust.
F6 Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F7 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Remarks:

President and Chief Executive Officer